Is there life after Avonex? That unlikely question is being posed to Biogen <% if gsSubBrand = "aolsnapshot" then Response.Write("(Nasdaq: BGEN)") else Response.Write("(Nasdaq: BGEN)") end if %> watchers -- bulls and bears alike. Which way will the $8 billion biotech giant turn? Not all Fools agree.
Paul Larson (TMF Parlay) and David Langford are Dueling Fools. Paul thinks the company will come back strong, while David is worried about the pipeline. Read the opening arguments. Read the rebuttals. Impress your friends with the right to vote once all has been said and done.
The Bull Argument...
I'm bullish on biotechnology, as well as Biogen <% if gsSubBrand = "aolsnapshot" then Response.Write("(Nasdaq: BGEN)") else Response.Write("(Nasdaq: BGEN)") end if %>, one of the industry's blue chips. Biotechnology in general and Biogen in particular have added an immeasurable amount of value for their customers by extending and improving the quality of life around the globe.
Continue »
Bear Argument...
Biogen's scant pipeline and evaporating sales have scared investors off, and for good reason: The future of any pharmaceutical biotech company is nothing more than its pipeline and the funding for it, and Biogen simply hasn't delivered on the promise of its spent research dollars.
Continue »
The Bull Argument »
